Use of Ibandronate in Diabetic Patients

NACompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

August 30, 2021

Study Completion Date

January 31, 2022

Conditions

Osteoporosis, PostmenopausalType 2 Diabetes

Interventions

DRUG

Ibandronate Oral Tablet

150 mg of ibandronate + 24,000 IU of cholecalciferol

Trial Locations (1)

Yeouido St.Mary's Hospital, Seoul

All Listed Sponsors

collaborator

Samsung Medical Center

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

lead

Yeouido St. Mary's Hospital

OTHER

NCT05266261 - Use of Ibandronate in Diabetic Patients | Biotech Hunter | Biotech Hunter